Covid19_manual_annotation  

PubMed:32938496 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue ForCovid19 correct word correct/standard/original word details tao:has_database_id
3 0-9 Chemical denotes Sarilumab inhibitor|drug MESH:C000592401
T173 17-33 Therapy denotes standard of care MESH:D059039
T168 42-47 Condition denotes early
4 61-79 Disease denotes COVID-19 pneumonia MESH:D000086382
T4 83-95 Severity denotes hospitalized
5 96-104 Species denotes patients Tax:9606
T230 161-188 TrialDesign denotes randomised controlled trial
78 210-218 Species denotes patients Tax:9606
T72 220-225 BecomeSevere denotes acute
T73 227-243 BecomeSevere denotes life-threatening
79 244-262 Disease denotes respiratory injury MESH:D012131
80 291-299 Species denotes SARS-CoV Tax:694009
T174 310-315 Species denotes viral
81 316-325 Disease denotes pneumonia
T176 349-363 Increase denotes over-exuberant
T175 364-372 Biological denotes cytokine
T178 382-397 Increase denotes Elevated levels
T177 401-406 Biological denotes blood
82 407-411 Gene denotes IL-6 Gene:3569
T12 477-483 BecomeSevere denotes severe
83 484-492 Disease denotes COVID-19 MESH:D000086382
T75 502-521 Chemical denotes Anti-IL6 inhibitors inhibitor|drug
T78 566-576 Prevent denotes preventing
T182 581-586 BecomeSevere denotes fatal
T76 603-620 Disease denotes acute respiratory http://purl.obolibrary.org/obo/MONDO_0001208
85 625-644 Disease denotes multi organ failure MESH:D009102
T77 655-658 Percent denotes 20%
T208 666-674 Disease denotes COVID-19 MESH:D000086382
87 675-683 Disease denotes infected MESH:D007239
88 684-692 Species denotes patients Tax:9606
T196 706-711 Chemical denotes their inhibitor|drug
T187 712-715 Therapy denotes use
T191 719-730 Order denotes prioritized
89 734-742 Species denotes patients Tax:9606
T22 748-754 BecomeSevere denotes severe
T79 755-777 Disease denotes interstitial pneumonia MESH:D017563
T81 779-798 Index denotes Brescia-COVID Scale
T86 805-808 Grade denotes 2-3
T88 815-820 BecomeSevere denotes hyper
T87 820-832 Disease denotes inflammation MESH:D007249
T188 866-874 Increase denotes elevated
93 875-878 Gene denotes IL6 Gene:3569
T24 886-893 Index denotes d-dimer MESH:C036309
T89 898-909 Severity denotes progressive
T25 910-917 Index denotes d-dimer MESH:C036309
T189 918-926 Increase denotes increase
T91 1044-1063 Chemical denotes anti-IL6 inhibitors inhibitor
T197 1167-1170 Therapy denotes use
T92 1174-1193 Chemical denotes anti-IL6 inhibitors inhibitor|drug
T93 1200-1213 Timing denotes earlier state
97 1225-1251 Disease denotes hyperinflammatory syndrome MESH:D061325
T198 1261-1271 BecomeReduce denotes beneficial
T199 1280-1285 NegativeRegulation denotes avoid
T200 1286-1297 PositiveRegulation denotes progressing
98 1301-1305 Disease denotes ARDS MESH:D012128
T94 1383-1398 Chemical denotes corticosteroids drug
T99464 1422-1425 Status_of_Care denotes SOC Standard of Care abbreviation MESH:D059039
T159 1433-1442 Therapy denotes treatment
99 1446-1464 Disease denotes COVID-19 pneumonia MESH:D000086382
T207 1503-1509 PositiveRegulation denotes better
T206 1510-1519 Therapy denotes treatment
T97 1560-1574 Chemical denotes IL6-inhibitors inhibitor|drug
101 1581-1590 Chemical denotes sarilumab inhibitor|drug MESH:C000592401
T95 1597-1612 Chemical denotes corticosteroids drug
T105 1664-1671 Timing denotes earlier
T103 1702-1711 Chemical denotes sarilumab inhibitor MESH:C000592401
T161 1717-1720 Therapy denotes SOC Standard of Care abbreviation MESH:D059039
T96 1732-1747 Chemical denotes corticosteroids
103 1837-1856 Disease denotes respiratory failure decreases MESH:D012131
104 1860-1868 Disease denotes COVID-19 MESH:D000086382
105 1869-1877 Disease denotes infected MESH:D007239
106 1878-1886 Species denotes patients Tax:9606
T80 1892-1914 Disease denotes interstitial pneumonia MESH:D017563
108 2041-2050 Chemical denotes sarilumab inhibitor MESH:C000592401
T99470 2077-2089 Disease denotes TRIAL DESIGN
T231 2093-2102 TrialDesign denotes phase two
T226 2103-2115 TrialDesign denotes multi-center
T227 2116-2143 TrialDesign denotes randomised controlled trial
T228 2145-2148 TrialDesign denotes RCT randomised controlled trial abbreviation
T233 2155-2158 Number denotes two
T232 2159-2172 TrialDesign denotes parallel arms
T234 2174-2177 Ratio denotes 1:1
T38 2213-2225 Severity denotes hospitalized trial criteria
110 2226-2234 Species denotes patients Tax:9606
T106 2239-2263 Age denotes at least 18 years of age trial criteria
T40 2270-2276 BecomeSevere denotes severe trial criteria
T209 2277-2285 Disease denotes COVID-19 trial criteria MESH:D000086382
T99468 2295-2303 Positive denotes positive
T43 2304-2310 Method denotes RT-PCR MESH:D020133
T107 2325-2337 Method denotes radiographic trial criteria
T99469 2338-2346 Positive denotes evidence
112 2350-2371 Disease denotes pulmonary infiltrates trial criteria MESH:D017254
T108 2386-2391 Disease denotes rales trial criteria MESH:D012135
T110 2392-2400 Disease denotes crackles trial criteria MESH:D012135
T111 2413-2417 Index denotes SpO2 trial criteria
T213 2418-2423 Percent denotes ≤ 94%
T112 2450-2469 Therapy denotes supplemental oxygen trial criteria
114 2471-2479 Species denotes Patients Tax:9606
115 2531-2535 Gene denotes IL-6 trial criteria Gene:3569
T113 2536-2546 Value denotes > 40 pg/mL trial criteria
T214 2550-2557 Index denotes d-dimer trial criteria MESH:C036309
T45 2558-2569 Value denotes >1.0 mcg/ml trial criteria
T215 2590-2611 BecomeSevere denotes progressive worsening
T116 2615-2627 Requirement denotes at least two trial criteria
T117 2674-2680 Duration denotes 24-48h trial criteria
116 2682-2685 Gene denotes CRP trial criteria Gene:1401
T114 2687-2690 Biological denotes LDH trial criteria
T115 2692-2706 Biological denotes serum ferritin trial criteria
117 2708-2719 Disease denotes lymphopenia trial criteria MESH:D008231
T46 2724-2731 Index denotes d-dimer trial criteria MESH:C036309
T119 2789-2813 Therapy denotes face mask with reservoir exclude
T121 2815-2850 Therapy denotes non-invasive mechanical ventilation exclude
T123 2854-2877 Therapy denotes high flow nasal cannula exclude
T125 2882-2904 Therapy denotes mechanical ventilation exclude
T131 2907-2923 Therapy denotes admission to ICU exclude
T127 2925-2934 Condition denotes pregnancy exclude
T129 2938-2947 Condition denotes lactation exclude
118 2949-2956 Disease denotes allergy exclude MESH:D004342
119 2960-2976 Disease denotes hypersensitivity exclude MESH:D004342
T101 2980-2989 Chemical denotes sarilumab exclude MESH:C000592401
T126 2993-3009 Chemical denotes corticoesteroids exclude
T133 3011-3045 Therapy denotes immunosuppressive antibody therapy exclude
T134 3057-3070 Duration denotes past 5 months
T135 3072-3086 Method denotes AST/ALT values exclude
T138 3087-3097 Value denotes > 10 x ULN
121 3099-3110 Disease denotes neutropenia exclude MESH:D009503
T136 3112-3125 Value denotes < 0.5 x 109/L
T47 3128-3134 BecomeSevere denotes severe
122 3135-3151 Disease denotes thrombocytopenia exclude MESH:D013921
T137 3153-3165 Value denotes < 50 x 109/L
123 3168-3174 Disease denotes sepsis exclude MESH:D018805
T216 3188-3208 Species denotes alternative pathogen
124 3210-3224 Disease denotes diverticulitis exclude MESH:D004238
T217 3253-3260 BecomeSevere denotes ongoing
T139 3261-3271 Disease denotes infectious MESH:D007239
125 3272-3282 Disease denotes dermatitis exclude MESH:D003872
T237 3284-3293 Trial denotes The study
T236 3315-3322 Number denotes several
T235 3323-3332 TrialDesign denotes hospitals
T140 3336-3341 Area denotes Spain
126 3372-3380 Species denotes Patients Tax:9606
T240 3381-3391 TrialDesign denotes randomised
T238 3399-3415 TrialDesign denotes experimental arm
127 3429-3438 Chemical denotes sarilumab inhibitor|drug MESH:C000592401
128 3441-3459 Chemical denotes methylprednisolone drug MESH:D008775
T162 3465-3468 Therapy denotes SOC Standard of Care abbreviation MESH:D059039
129 3473-3481 Disease denotes COVID-19 MESH:D000086382
130 3483-3491 Species denotes Patients Tax:9606
T239 3508-3519 TrialDesign denotes control arm
131 3533-3551 Chemical denotes methylprednisolone drug MESH:D008775
T164 3557-3560 Therapy denotes SOC Standard of Care abbreviation MESH:D059039
T210 3565-3573 Disease denotes COVID-19 MESH:D000086382
T171 3599-3604 Dose denotes given
T218 3608-3611 Target denotes all
133 3612-3620 Species denotes patients Tax:9606
T143 3626-3634 Amount denotes 1mg/kg/d
134 3638-3656 Chemical denotes methylprednisolone drug MESH:D008775
T142 3661-3676 Period denotes at least 3 days
135 3774-3782 Species denotes Patients Tax:9606
T99465 3790-3803 TrialDesign denotes control group
T165 3805-3808 Therapy denotes SOC Standard of Care abbreviation MESH:D059039
136 3823-3832 Chemical denotes sarilumab exclude MESH:C000592401
T82 3849-3863 Index denotes Brescia- COVID
T145 3864-3867 Grade denotes 2-3
138 3939-3948 Chemical denotes sarilumab inhibitor MESH:C000592401
139 4100-4109 Chemical denotes sarilumab inhibitor MESH:C000592401
140 4134-4142 Species denotes Patients Tax:9606
T99466 4143-4163 TrialDesign denotes randomly assigned to
141 4164-4173 Chemical denotes sarilumab inhibitor MESH:C000592401
T99467 4174-4181 TrialDesign denotes therapy
T83 4209-4222 Index denotes Brescia-COVID
T146 4223-4226 Grade denotes 2-3
143 4341-4349 Species denotes patients Tax:9606
T220 4439-4456 Index denotes Primary end point
T221 4464-4474 Proportion denotes proportion
144 4478-4486 Species denotes patients Tax:9606
T66 4509-4515 BecomeSevere denotes severe
145 4516-4535 Disease denotes respiratory failure MESH:D012131
T85 4537-4550 Index denotes Brescia-COVID
T147 4551-4553 Grade denotes ≥2
T148 4556-4569 BecomeSevere denotes ICU admission
T219 4574-4579 Die denotes death MESH:D003643
T222 4870-4873 Target denotes All
T149 4874-4885 Chemical denotes study drugs drug
T223 4910-4920 TrialDesign denotes open label
T241 4922-4941 TrialDesign denotes No blinding methods
T242 5014-5032 TrialDesign denotes target sample size
T150 5041-5044 Number denotes 200 trial criteria
T212 5045-5053 Disease denotes COVID-19 MESH:D000086382
149 5054-5062 Species denotes patients Tax:9606
T224 5098-5109 TrialDesign denotes control arm
T169 5111-5114 Number denotes 100 trial criteria
T225 5120-5133 TrialDesign denotes treatment arm
T170 5135-5138 Number denotes 100 trial criteria
R101 93 T188 of_a IL6,elevated
R102 T24 T188 of_a d-dimer,elevated
R104 T89 T189 of_a progressive,increase
R105 T25 T189 of_a d-dimer,increase
R108 T79 89 has_a interstitial pneumonia,patients
R111 89 T187 for patients,use
R116 T196 T187 of_a their,use
R117 T196 T75 coreference their,Anti-IL6 inhibitors
R118 T92 T197 of_a anti-IL6 inhibitors,use
R119 T197 T198 is_a use,beneficial
R123 T93 97 of_a earlier state,hyperinflammatory syndrome
R124 97 T197 for hyperinflammatory syndrome,use
R135 T207 T206 of_a better,treatment
R137 T178 T12 cause_of Elevated levels,severe
R138 82 T178 of_a IL-6,Elevated levels
R139 82 T178 of_a IL-6,Elevated levels
R140 T208 87 of_a COVID-19,infected
R141 79 78 has_a respiratory injury,patients
R142 T175 T176 cause_of cytokine,over-exuberant
R143 79 T176 relates respiratory injury,over-exuberant
R144 T182 T76 is_a fatal,acute respiratory
R145 T182 85 is_a fatal,multi organ failure
R146 T78 T182 cause_of preventing,fatal
R147 T75 T78 is_a Anti-IL6 inhibitors,preventing
R148 T191 T187 of_a prioritized,use
R149 T188 T87 cause_of elevated,inflammation
R150 T189 T87 cause_of increase,inflammation
R151 T200 98 is_a progressing,ARDS
R152 T199 T200 is_a avoid,progressing
R153 T94 T159 of_a corticosteroids,treatment
R156 T38 110 of_a hospitalized,patients
R157 T106 110 of_a at least 18 years of age,patients
R158 T40 T209 of_a severe,COVID-19
R159 T209 110 has_a COVID-19,patients
R165 T213 T111 of_a ≤ 94%,SpO2
R166 112 110 has_a pulmonary infiltrates,patients
R167 T111 110 of_a SpO2,patients
R168 T213 T112 cause_of ≤ 94%,supplemental oxygen
R169 T113 115 of_a > 40 pg/mL,IL-6
R170 T45 T214 of_a >1.0 mcg/ml,d-dimer
R171 T117 T116 in 24-48h,at least two
R172 T215 116 is_a progressive worsening,CRP
R17297 T87 89 has_a inflammation,patients
R173 T215 T114 is_a progressive worsening,LDH
R174 T215 T115 is_a progressive worsening,serum ferritin
R175 T215 117 is_a progressive worsening,lymphopenia
R176 T215 T46 is_a progressive worsening,d-dimer
R177 116 T116 with CRP,at least two
R178 T114 T116 with LDH,at least two
R179 T115 T116 with serum ferritin,at least two
R180 117 T116 with lymphopenia,at least two
R181 T46 T116 with d-dimer,at least two
R182 T126 119 for corticoesteroids,hypersensitivity
R183 T101 119 for sarilumab,hypersensitivity
R184 T134 T133 in past 5 months,immunosuppressive antibody therapy
R185 T138 T135 of_a > 10 x ULN,AST/ALT values
R186 T136 121 of_a < 0.5 x 109/L,neutropenia
R187 T137 122 of_a < 50 x 109/L,thrombocytopenia
R188 T47 122 of_a severe,thrombocytopenia
R189 T216 123 by alternative pathogen,sepsis
R190 104 105 of_a COVID-19,infected
R191 105 106 has_a infected,patients
R192 T217 125 of_a ongoing,dermatitis
R193 T139 125 of_a infectious,dermatitis
R194 129 126 has_a COVID-19,Patients
R195 T210 130 has_a COVID-19,Patients
R200 T210 130 for COVID-19,Patients
R201 T218 133 of_a all,patients
R2012 T199 T197 of_a avoid,use
R202 134 T171 of_a methylprednisolone,given
R203 T143 T171 of_a 1mg/kg/d,given
R204 T142 T171 of_a at least 3 days,given
R205 133 T171 of_a patients,given
R207 T66 145 of_a severe,respiratory failure
R208 145 144 has_a respiratory failure,patients
R209 T148 144 of_a ICU admission,patients
R210 T219 144 is_a death,patients
R211 T220 T221 is_a Primary end point,proportion
R212 144 T221 of_a patients,proportion
R213 T222 T149 of_a All,study drugs
R214 T223 T149 of_a open label,study drugs
R215 T212 149 has_a COVID-19,patients
R216 T150 149 of_a 200,patients
R217 T224 T169 of_a control arm,100
R218 T225 T170 of_a treatment arm,100
R221 4 T173 for COVID-19 pneumonia,standard of care
R222 4 3 for COVID-19 pneumonia,Sarilumab
R223 T168 T173 of_a early,standard of care
R224 T168 3 of_a early,Sarilumab
R226 T233 T232 of_a two,parallel arms
R22628 T199 T197 of_a avoid,use
R228 T236 T235 of_a several,hospitals
R229 T235 T237 of_a hospitals,The study
R230 T140 T237 in Spain,The study
R231 127 T238 with sarilumab,experimental arm
R232 128 T238 with methylprednisolone,experimental arm
R233 T162 T238 with SOC,experimental arm
R234 T238 126 of_a experimental arm,Patients
R235 T239 130 in control arm,Patients
R236 131 T239 with methylprednisolone,control arm
R237 T164 T239 with SOC,control arm
R238 T240 T238 of_a randomised,experimental arm
R239 T240 T239 of_a randomised,control arm
R24 106 T80 of_a patients,interstitial pneumonia
R240 T150 T242 of_a 200,target sample size
R241 T234 T233 of_a 1:1,two
R33921 T159 T99464 has_status treatment,SOC
R44 T83 T146 of_a Brescia-COVID,2-3
R44004 101 T97 is_a sarilumab,IL6-inhibitors
R61172 101 T207 cause_of sarilumab,better
R62 T4 5 of_a hospitalized,patients
R65 81 79 cause_of pneumonia,respiratory injury
R66 T174 81 by viral,pneumonia
R66389 99 T159 for COVID-19 pneumonia,treatment
R66390 T99465 135 in control group,Patients
R66391 T145 T82 of_a 2-3,Brescia- COVID
R66392 T99466 T99467 - randomly assigned to,therapy
R66393 T147 T85 of_a ≥2,Brescia-COVID
R66394 T107 T99469 using radiographic,evidence
R66395 T99469 112 is_a evidence,pulmonary infiltrates
R66396 T99468 T209 is_a positive,COVID-19
R66397 T43 T99468 using RT-PCR,positive
R66398 T108 T99469 relates rales,evidence
R66399 T110 T99469 relates crackles,evidence
R66400 T228 T227 abbreviation RCT,randomised controlled trial
R67 80 81 by SARS-CoV,pneumonia
R68 T72 79 is_a acute,respiratory injury
R69 T73 79 is_a life-threatening,respiratory injury
R7222 T199 T197 cause_of avoid,use
R75 T177 82 in blood,IL-6
R76 T12 83 is_a severe,COVID-19
R86224 T97 T207 cause_of IL6-inhibitors,better
R88 4 5 has_a COVID-19 pneumonia,patients
R90 87 88 has_a infected,patients
R92 T77 88 of_a 20%,patients
R93 T76 88 has_a acute respiratory,patients
R94 85 88 has_a multi organ failure,patients
R95 T22 T79 of_a severe,interstitial pneumonia
R96 T86 T81 of_a 2-3,Brescia-COVID Scale
R96893 T95 T207 cause_of corticosteroids,better
R97 T81 T22 is_a Brescia-COVID Scale,severe
R98 T88 T87 of_a hyper,inflammation